Lemaitre Vascular opened higher at $79.41, compared with its previous close of $79.29. In the last trading session, the stock traded between $77.46 and $79.76. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Lemaitre Vascular is now worth
$ 143.15
Giving a profit of
$ 43.15 (43.15%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-1.73 (-2.19%)
Day High
$79.76
Day Low
$77.46
Day Open
$79.41
Prev Close
$79.29
Volume
1,23,300
1W Return
-11.76%
1M Return
-6.42%
3M Return
-6.38%
6M Return
-23.69%
1Y Return
-14.18%
Market Cap ($ Mn)
1,775
PE Ratio
28.23
PB Ratio
4.38
PEG Ratio
1.85
ROE
15.86%
ROCE
14.65%
EPS (TTM)
$0.66
1 Week
-11.76%
1 Month
-6.42%
3 Months
-6.38%
6 Months
-23.69%
9 Months
-11.65%
Citizens maintains outperform on LeMaitre Vascular, cuts target
Citizens analyst Daniel Stauder maintains Market Outperform rating on LeMaitre Vascular. Price target reduced from $127 to $110. Rating remains unchanged despite lower price objective.
7 days agoLeMaitre Vascular Q3FY26 Results: Organic sales grow 12%, EPS hits $0.65
Organic sales grew 12% in Q3 FY26, driven by 7% price increases and 5% unit volume growth. Fully diluted EPS reached $0.65, with net income of $15 million and free cash flow of $19.7 million. Gross margin improved 90 bps YoY to 71.7%, aided by higher ASPs and lower shipping costs. Full-year guidance reiterated for 11% organic revenue growth and 18% EPS growth despite FX headwinds. Acquired B. Braun vascular device portfolio for $19.2 million, expecting $9.4 million in annual sales.
8 days agoLeMaitre Vascular data breach: Law firm probes class action claims
Edelson Lechtzin LLP is investigating a data breach at LeMaitre Vascular reported on September 18, 2026. At least two Vermont residents are confirmed to be affected by the security incident. Exposed data may include Social Security numbers, government IDs, and health records. The company has not disclosed exact dates of the breach or its discovery.
1mo agoLeMaitre CFO to address investors at three major healthcare conferences
LeMaitre Vascular Inc (NASDAQ: LMAT) CFO Dorian LeBlanc to speak at three investor conferences. First session is a fireside chat at Wells Fargo conference on September 8, 2026 in Boston. Second appearance is at Morgan Stanley conference on September 16, 2026 in New York City. Final engagement is at the virtual Barrington Research conference on September 22, 2026. Company treats peripheral vascular disease affecting over 200 million people globally.
2mo agoLeMaitre Vascular management to hold investor meetings at Needham conference
LeMaitre Vascular, Inc. will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. The Burlington-based company provides vascular devices for treating peripheral vascular disease, which affects over 200 million people globally. This engagement allows management to discuss strategy and performance with stakeholders.
3mo agoLeMaitre Vascular to announce Q2 2026 earnings on August 4
LeMaitre Vascular will announce its Q2 2026 financial results on August 4, 2026, after market close, followed by a conference call at 5:00 PM EDT to discuss performance and outlook.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Lemaitre Vascular is now worth
$ 143.15
Giving a profit of
$ 43.15 (43.15%)
Note: Past profits do not guarantee future returns.
